SK73898A3 - Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation - Google Patents

Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation Download PDF

Info

Publication number
SK73898A3
SK73898A3 SK738-98A SK73898A SK73898A3 SK 73898 A3 SK73898 A3 SK 73898A3 SK 73898 A SK73898 A SK 73898A SK 73898 A3 SK73898 A3 SK 73898A3
Authority
SK
Slovakia
Prior art keywords
group
formula
compound
salt
solvate
Prior art date
Application number
SK738-98A
Other languages
English (en)
Slovak (sk)
Inventor
Scott E Zook
Raymond Dagnino Jr
Michael E Deason
Steven L Bender
Michael J Melnick
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of SK73898A3 publication Critical patent/SK73898A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/04—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SK738-98A 1995-12-08 1996-12-05 Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation SK73898A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56976695A 1995-12-08 1995-12-08
PCT/US1996/019328 WO1997020824A1 (fr) 1995-12-08 1996-12-05 Inhibiteurs de metalloproteinases, compositions pharmaceutiques contenant ces inhibiteurs et leurs utilisations pharmaceutiques, et procedes et intermediaires servant a leur preparation

Publications (1)

Publication Number Publication Date
SK73898A3 true SK73898A3 (en) 1999-01-11

Family

ID=24276764

Family Applications (1)

Application Number Title Priority Date Filing Date
SK738-98A SK73898A3 (en) 1995-12-08 1996-12-05 Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation

Country Status (39)

Country Link
US (1) US6153757A (fr)
EP (2) EP1095936B1 (fr)
JP (1) JP2000502330A (fr)
KR (1) KR19990072009A (fr)
CN (2) CN1207289C (fr)
AP (2) AP1368A (fr)
AT (2) ATE283264T1 (fr)
AU (1) AU725831C (fr)
BG (1) BG64279B1 (fr)
BR (1) BR9611929A (fr)
CA (1) CA2238306A1 (fr)
CO (1) CO4790150A1 (fr)
CZ (1) CZ292942B6 (fr)
DE (2) DE69626684T2 (fr)
DK (1) DK0874830T3 (fr)
EA (1) EA003294B1 (fr)
ES (2) ES2195034T3 (fr)
GE (1) GEP20012388B (fr)
GT (2) GT199700015A (fr)
HR (1) HRP970031A2 (fr)
HU (1) HUP9902092A3 (fr)
ID (1) ID17624A (fr)
IL (6) IL138027A (fr)
MX (1) MX9804457A (fr)
MY (1) MY117290A (fr)
NO (1) NO311360B1 (fr)
NZ (1) NZ325559A (fr)
OA (1) OA10794A (fr)
PA (1) PA8431301A1 (fr)
PE (1) PE69298A1 (fr)
PL (1) PL327275A1 (fr)
PT (1) PT874830E (fr)
SI (1) SI0874830T1 (fr)
SK (1) SK73898A3 (fr)
SV (1) SV1997000008A (fr)
TR (1) TR199800990T2 (fr)
TW (1) TW546293B (fr)
WO (1) WO1997020824A1 (fr)
YU (1) YU21597A (fr)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
DK0874830T3 (da) * 1995-12-08 2003-04-22 Agouron Pharma Metalloproteinaseinhibitor, farmaceutisk præparat indeholdende denne og den farmaceutiske anvendelse samt en fremgangsmåde til fremstilling deraf
US6747027B1 (en) 1996-07-22 2004-06-08 Pharmacia Corporation Thiol sulfonamide metalloprotease inhibitors
CN1230884A (zh) * 1996-07-22 1999-10-06 孟山都公司 硫羟砜金属蛋白酶抑制剂
BR9712792A (pt) * 1996-08-28 1999-12-14 Procter & Gamble Inibidores de metaloprotease bidentada.
ES2201318T3 (es) 1996-08-28 2004-03-16 THE PROCTER & GAMBLE COMPANY Inhibidores de metaloproteasas de aminas ciclicas substituidas.
TR199900383T2 (xx) * 1996-08-28 1999-05-21 The Procter & Gamble Company 1,3-Diheterosiklik metaloproteaz inhibit�rleri.
DK0923561T3 (da) * 1996-08-28 2003-02-24 Procter & Gamble Heterocykliske metalloproteaseinhibitorer
US6872742B2 (en) 1996-08-28 2005-03-29 The Procter & Gamble Company Substituted cyclic amine metalloprotease inhibitors
NZ334252A (en) * 1996-08-28 2000-11-24 Procter & Gamble Heterocyclic metalloprotease inhibitors
US5977408A (en) * 1996-10-16 1999-11-02 American Cyanamid Company Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US6548524B2 (en) 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5962481A (en) * 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
KR20000049197A (ko) * 1996-10-16 2000-07-25 윌리암 에이취 캘넌, 에곤 이 버그 매트릭스 메탈로프로테이나제 및 종양 괴사 인자-α 전환 효소억제제로서의 오르토-설폰아미도 헤테로아릴 하이드록삼산의 제조 및 용도
US6228869B1 (en) 1996-10-16 2001-05-08 American Cyanamid Company Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5929097A (en) * 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
JP2001506257A (ja) 1996-12-17 2001-05-15 藤沢薬品工業株式会社 Ｍｍｐまたはｔｎｆ阻害剤としてのピペラジン化合物
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
WO1998039315A1 (fr) 1997-03-04 1998-09-11 Monsanto Company Composes aromatiques d'acide sulfonyl alpha-cycloamino hydroxamique
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6087359A (en) * 1997-03-04 2000-07-11 Getman; Daniel P. Thioaryl sulfonamide hydroxamic acid compounds
US6794511B2 (en) 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
JP2002513408A (ja) * 1997-03-04 2002-05-08 モンサント カンパニー チオールスルホンアミドヒドロキサム酸化合物
WO1998039316A1 (fr) 1997-03-04 1998-09-11 Monsanto Company Composes n-hydroxy-4-sulfonyl-butanamide
EP0983257A4 (fr) 1997-03-04 2001-05-02 Monsanto Co Composes aromatiques d'acide sulfonyl alpha-cycloamino hydroxamique
CA2285372A1 (fr) * 1997-04-01 1998-10-08 Melwyn A. Abreo Inhibiteurs de metalloproteinases, compositions pharmaceutiques les contenant et leurs utilisations pharmaceutiques
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
WO1998050348A1 (fr) * 1997-05-09 1998-11-12 Agouron Pharmaceuticals, Inc. Inhibiteurs de metalloproteases, compositions pharmaceutiques les contenant et leurs utilisations pharmaceutiques
JP2004137284A (ja) * 1997-06-17 2004-05-13 Kaken Pharmaceut Co Ltd ２−スルファモイル安息香酸誘導体
BR9810841A (pt) 1997-07-31 2001-07-10 Procter & Gamble Inibidores de metaloprotease alicìclicos
US6403632B1 (en) * 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
JPH11199512A (ja) * 1997-10-24 1999-07-27 Pfizer Prod Inc 変形性関節症および他のｍｍｐ媒介疾患の治療のためのｍｍｐ−１３選択的阻害剤の使用
BR9814643A (pt) 1997-11-14 2000-10-03 Searle & Co Inibidor de metaloprotease de ácido sulfona hidroxâmico aromático
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6071903A (en) * 1998-01-27 2000-06-06 American Cyanamid Company 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
CN1293663A (zh) * 1998-01-27 2001-05-02 美国氰胺公司 为基质金属蛋白酶抑制剂的2,3,4,5－四氢－1h－[1,4]苯并二氮杂䓬－3－异羟肟酸
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
CN1195735C (zh) 1998-02-04 2005-04-06 诺瓦提斯公司 抑制使基质退化的金属蛋白酶的磺酰氨基衍生物
US6329418B1 (en) * 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
WO1999058531A1 (fr) * 1998-05-14 1999-11-18 Du Pont Pharmaceuticals Company Nouveaux acides hydroxamiques a substitution aryle en tant qu'inhibiteurs de metalloproteinase
WO1999065867A1 (fr) * 1998-06-17 1999-12-23 Du Pont Pharmaceuticals Company Acides hydroxamiques cycliques utilises en tant qu'inhibiteurs de metalloproteases
EP1357109B1 (fr) 1998-06-18 2008-07-23 F. Hoffmann-La Roche Ag Procédé pour sulfide aryle alcoyle
FR2780402B1 (fr) * 1998-06-30 2001-04-27 Adir Nouveaux composes acides carboxyliques et hydroxamiques inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UA59453C2 (uk) * 1998-08-12 2003-09-15 Пфайзер Продактс Інк. Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
JP3623448B2 (ja) * 1998-08-12 2005-02-23 ファイザー・プロダクツ・インク Ｔａｃｅインヒビター
US6509337B1 (en) * 1998-09-17 2003-01-21 Pfizer Inc. Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
WO2000018361A2 (fr) * 1998-09-30 2000-04-06 The Procter & Gamble Company Procede de traitement de la chute de cheveux par administration de sulfonamides
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6288261B1 (en) * 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6858598B1 (en) * 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
WO2000038730A2 (fr) * 1998-12-23 2000-07-06 G.D. Searle & Co. Techniques permettant d'utiliser un inhibiteur de cyclooxygenase-2 et un ou plusieurs agents antineoplasiques comme therapie combinee pour traiter les maladies neoplasiques
CN1178915C (zh) 1999-01-27 2004-12-08 惠氏控股有限公司 含有炔基的异羟肟酸衍生物、其制备及其作为基质金属蛋白酶抑制剂/TNF-α转变酶抑制剂的用途
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6544984B1 (en) 1999-01-27 2003-04-08 American Cyanamid Company 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids
AR022423A1 (es) * 1999-01-27 2002-09-04 American Cyanamid Co Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
AU775701B2 (en) 1999-02-08 2004-08-12 G.D. Searle & Co. Sulfamato hydroxamic acid metalloprotease inhibitor
EP1165501A1 (fr) 1999-03-03 2002-01-02 The Procter & Gamble Company Inhibiteurs de metalloproteases, contenant alcenyle et alcynale
CZ20013155A3 (cs) 1999-03-03 2002-01-16 The Procter & Gamble Company Inhibitory metaloproteas
AUPP982399A0 (en) * 1999-04-19 1999-05-13 Fujisawa Pharmaceutical Co., Ltd. Mmp inhibitor
US6583299B1 (en) 1999-05-20 2003-06-24 G.D. Searle & Co. α-amino-β-sulfonyl hydroxamic acid compounds
US6869951B1 (en) 1999-07-16 2005-03-22 Pharmacia Corporation Method of changing conformation of a matrix metalloproteinase
AR033651A1 (es) 1999-10-01 2004-01-07 Hoffmann La Roche Derivados de pirimidina-2,4,6-triona, composiciones farmaceuticas que contienen dichos compuestos y el empleo de los mismos para la manufactura de un medicamento
IL151018A0 (en) * 2000-03-17 2003-02-12 Bristol Myers Squibb Pharma Co Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
MXPA02009020A (es) 2000-03-17 2003-02-12 Du Pont Pharm Co Derivados de beta-aminoacidos ciclicos como inhibidores de las metaloproteasas de matriz y factor de necrosis de tumor alfa.
EP1138680A1 (fr) * 2000-03-29 2001-10-04 Pfizer Products Inc. Acides gem-substitués alpha-sulfonylamino hydroxamiques comme inhibiteurs de métalloprotease
DE60120881T2 (de) * 2000-04-07 2007-01-18 Samsung Electronics Co., Ltd., Suwon Sulfonamide als matrix-metalloproteinase inhibitoren
US6683093B2 (en) 2000-05-12 2004-01-27 Pharmacia Corporation Aromatic sulfone hydroxamic acids and their use as protease inhibitors
US6927216B2 (en) 2000-10-03 2005-08-09 Bristol-Myers Squibb Pharma Company Cyclic sulfonyl compounds as inhibitors of metalloproteases
FR2819252A1 (fr) * 2001-01-11 2002-07-12 Servier Lab Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1355901A2 (fr) 2001-01-11 2003-10-29 Bristol-Myers Squibb Pharma Company Inhibiteurs cycliques 1,1-disubstitues des metalloproteases matricielles et de tnf-$g(a)
WO2002055491A2 (fr) 2001-01-11 2002-07-18 Bristol Myers Squibb Company P Inhibiteurs cycliques a disubstitution en position 1,2 de metalloproteases matricielles et de tnf alpha
MXPA01013326A (es) 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
CA2439539A1 (fr) 2001-03-15 2002-09-26 Matthew E. Voss Derives de beta-aminoacides spirocycliques utilises comme inhibiteurs des metalloproteinases matricielles et de l'enzyme de conversion de tnf-alpha (tage)
US6716845B2 (en) 2001-03-30 2004-04-06 Hoffmann-La Roche Inc. Barbituric acid derivatives
YU85403A (sh) 2001-05-11 2006-03-03 Pharmacia Corporation Aromatični sulfonski hidroksamati i njihova upotreba kao proteaznih inhibitora
US20030203890A1 (en) * 2001-05-29 2003-10-30 Steiner Joseph P. Method for treating nerve injury caused as a result of surgery
US6683078B2 (en) 2001-07-19 2004-01-27 Pharmacia Corporation Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
AUPR726201A0 (en) * 2001-08-24 2001-09-20 Fujisawa Pharmaceutical Co., Ltd. New use of a cyclic compound
JP2003081937A (ja) * 2001-09-07 2003-03-19 Bayer Ag ベンゼンスルホンアミド誘導体
BR0213736A (pt) 2001-11-01 2004-10-19 Wyeth Corp ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace
AU2002356979A1 (en) * 2001-11-30 2003-06-17 Bristol-Myers Squibb Company Method of producing n-((2s)-sulfanyl-4-(1,5,5-trimethylhydantoinyl)butanoyl)-l-leucyl-l-tert-leucine n-methylamide and intermediate thereof
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
AU2003221786A1 (en) 2002-04-25 2003-11-10 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
WO2003104224A1 (fr) * 2002-06-10 2003-12-18 Pfizer Inc. Metabolites de prinomastat et synthese de ceux-ci
EP1511488B1 (fr) * 2002-06-12 2013-05-22 Symphony Evolution, Inc. Inhibiteurs humains d'adam 10
CA2490646A1 (fr) * 2002-06-25 2003-12-31 Pharmacia Corporation Derives amide et acide arylsulfonylhydroxamique, utilisation de ces derniers en tant qu'inhibiteurs de proteases
AU2003304456A1 (en) 2002-12-23 2005-03-16 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
EP1592389B1 (fr) * 2003-02-14 2009-04-22 Laboratoires Serono SA Derives de piperazine-2-carboxamide
JP2006517960A (ja) * 2003-02-18 2006-08-03 ファイザー インコーポレイテッド Ｃ型肝炎ウイルスの阻害剤、それを使用する組成物および治療法
CN1802159B (zh) 2003-03-24 2013-04-24 阿克西金药品公司 治疗哮喘及其它炎症或免疫性疾病的具有ccr3拮抗活性的2-苯氧基-和2-苯基磺酰胺衍生物
GT200500139A (es) * 2004-06-08 2005-07-25 Metodo para la preparacion de acidos hidroxamicos
WO2007141029A1 (fr) * 2006-06-08 2007-12-13 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Inhibiteurs spécifiques de protéase et leur utilisation pour le traitement du cancer
US8426415B2 (en) 2007-10-16 2013-04-23 Symphony Evolution, Inc. Human ADAM-10 inhibitors
EP2147684A1 (fr) * 2008-07-22 2010-01-27 Bracco Imaging S.p.A Agents de diagnostics sélectifs contre les métalloprotéases
WO2011081884A1 (fr) 2009-12-14 2011-07-07 Massachusetts Institute Of Technology Systèmes et procédés concernant des nanocapteurs optiques comprenant des nanostructures photoluminescentes
IT1401253B1 (it) 2010-04-23 2013-07-18 Uni Degli Studi Carlo Bo Urbino Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.
JP2014528963A (ja) * 2011-10-04 2014-10-30 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） 新規のアポトーシス誘導化合物
CN113194954A (zh) 2018-10-04 2021-07-30 国家医疗保健研究所 用于治疗角皮病的egfr抑制剂
KR20220004096A (ko) 2019-04-26 2022-01-11 닛산 가가쿠 가부시키가이샤 아릴술폰산 에스테르 화합물의 제조 방법
WO2020252439A1 (fr) * 2019-06-14 2020-12-17 Loyola University Of Chicago Agents de métalloprotéinase matricielle d'acide hydroxamique carborane pour une thérapie de capture de neutrons de bore

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032639A (en) * 1976-03-22 1977-06-28 American Home Products Corporation 2,3,4,4A-Tetrahydro-1H-pyrazino[1,2-a,]quinoxalin-5(6H)-ones and derivatives thereof for relieving hypertension
ZW23187A1 (en) * 1986-12-15 1988-06-29 Hoffmann La Roche Phosphinic acid derivatives
GB9000846D0 (en) * 1990-01-15 1990-03-14 Beecham Group Plc Novel compounds
GB9022117D0 (en) * 1990-10-11 1990-11-21 Beecham Group Plc Novel compounds
US5239078A (en) * 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
DE69108363T2 (de) * 1990-12-03 1995-08-31 Celltech Ltd Peptidylderivate.
CA2102890A1 (fr) * 1991-05-28 1992-11-29 Soumya P. Sahoo Derives n-carboxyalkylpeptidyles substitues utilises comme agents antidegeneratifs
US5256657A (en) * 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5376664A (en) * 1992-07-27 1994-12-27 The Du Pont Merck Pharmaceutical Company Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agents
CA2149640A1 (fr) * 1992-11-25 1994-06-09 Kevin T. Chapman Derives carboxypeptidyles utilises comme agents anti-degeneratifs
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9307956D0 (en) * 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
GB9308695D0 (en) * 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
US6013792A (en) * 1993-08-05 2000-01-11 Syntex (U.S.A.), Inc. Matrix metalloprotease inhibitors
CA2168791A1 (fr) * 1993-08-05 1995-02-16 Arlindo L. Castelhano Inhibiteurs de la metalloprotease de la matrice
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
UA48121C2 (uk) * 1993-11-04 2002-08-15 Сінтекс (С.Ш.А.) Інк. Інгібітори матричних металопротеаз і фармацетична композиція на їх основі
CA2181709A1 (fr) * 1994-01-22 1995-07-27 Raymond Paul Beckett Derives de l'acide hydroxamique en tant qu'inhibiteurs de metalloproteinase
US5514716A (en) * 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
ATE181055T1 (de) * 1994-05-28 1999-06-15 British Biotech Pharm Succinyl hydroxamsäure-, n-formyl-n-hydroxy- aminocarbonsäure- und succinsäureamid-derivate und ihre verwendung als metalloprotease- inhibitoren
DK0766665T3 (da) * 1994-06-22 1999-12-06 British Biotech Pharm Metalloproteinaseinhibitorer
GB9416897D0 (en) * 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
JP3053222B2 (ja) * 1995-04-20 2000-06-19 ファイザー・インコーポレーテッド Ｍｍｐおよびｔｎｆ抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
KR980009238A (ko) * 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
PT757984E (pt) * 1995-08-08 2003-02-28 Ono Pharmaceutical Co Derivados de acido hidroxamico uteis para inibir a gelatinase
DE19542189A1 (de) * 1995-11-13 1997-05-15 Hoechst Ag Cyclische N-substituierte alpha-Iminohydroxamsäuren
BR9611479B1 (pt) * 1995-11-13 2009-01-13 Ácidos alfa-iminoidroxÂmicos e carboxÍlicos n-substituÍdos cÍclicos e heterocÍclicos.
PL326700A1 (en) * 1995-11-17 1998-10-26 Warner Lambert Co Sulphonamide-based inhibitors of intercellular substance metaloproteinases
US5753653A (en) * 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
DK0874830T3 (da) * 1995-12-08 2003-04-22 Agouron Pharma Metalloproteinaseinhibitor, farmaceutisk præparat indeholdende denne og den farmaceutiske anvendelse samt en fremgangsmåde til fremstilling deraf
TW453995B (en) * 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
ATE225343T1 (de) * 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
DE69619865T2 (de) * 1995-12-22 2002-11-07 Warner Lambert Co Aromatische keto-säure und ihre derivate als inhibitoren der matrix metalloproteinase
US5837224A (en) * 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin
SK282995B6 (sk) * 1996-01-23 2003-01-09 Shionogi And Co., Ltd. Zlúčenina na inhibíciu metaloproteázy a prostriedok s jej obsahom
SK21499A3 (en) * 1996-08-23 2000-05-16 Pfizer Arylsulfonylamino hydroxamic acid derivatives
NZ334252A (en) * 1996-08-28 2000-11-24 Procter & Gamble Heterocyclic metalloprotease inhibitors
ES2201318T3 (es) * 1996-08-28 2004-03-16 THE PROCTER & GAMBLE COMPANY Inhibidores de metaloproteasas de aminas ciclicas substituidas.
US5929097A (en) * 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses

Also Published As

Publication number Publication date
NZ325559A (en) 2000-01-28
SI0874830T1 (en) 2003-08-31
EA003294B1 (ru) 2003-04-24
GEP20012388B (en) 2001-03-25
DE69633947T2 (de) 2005-12-01
ATE234291T1 (de) 2003-03-15
US6153757A (en) 2000-11-28
BG64279B1 (bg) 2004-08-31
IL138027A (en) 2004-08-31
EP1095936B1 (fr) 2004-11-24
ES2233275T3 (es) 2005-06-16
SV1997000008A (es) 1999-02-15
CN1207289C (zh) 2005-06-22
CA2238306A1 (fr) 1997-06-12
BG102510A (en) 1999-08-31
PT874830E (pt) 2003-06-30
AU1409197A (en) 1997-06-27
OA10794A (en) 2001-07-05
MY117290A (en) 2004-06-30
EP0874830B1 (fr) 2003-03-12
PL327275A1 (en) 1998-12-07
IL138028A0 (en) 2001-10-31
GT199700015A (es) 1998-07-23
DE69626684T2 (de) 2004-04-29
YU21597A (en) 1999-11-22
JP2000502330A (ja) 2000-02-29
HRP970031A2 (en) 1998-08-31
AP2001002270A0 (en) 2001-09-30
IL143674A0 (en) 2002-04-21
IL138027A0 (en) 2001-10-31
IL124559A0 (en) 1998-12-06
CN1207734A (zh) 1999-02-10
HUP9902092A2 (hu) 1999-09-28
EP0874830A1 (fr) 1998-11-04
MX9804457A (es) 1998-09-30
AP1368A (en) 2005-04-21
IL124559A (en) 2004-07-25
NO311360B1 (no) 2001-11-19
AU725831C (en) 2002-10-17
BR9611929A (pt) 1999-05-18
TR199800990T2 (xx) 1998-07-21
ID17624A (id) 1998-01-15
EA199800541A1 (ru) 1998-12-24
DK0874830T3 (da) 2003-04-22
ATE283264T1 (de) 2004-12-15
CZ292942B6 (cs) 2004-01-14
CZ173398A3 (cs) 1998-11-11
KR19990072009A (ko) 1999-09-27
PA8431301A1 (es) 2000-05-24
PE69298A1 (es) 1998-11-13
AP1288A (en) 2004-07-21
IL134816A (en) 2003-02-12
ES2195034T3 (es) 2003-12-01
CO4790150A1 (es) 1999-05-31
IL134816A0 (en) 2001-05-20
TW546293B (en) 2003-08-11
DE69626684D1 (de) 2003-04-17
GT199700015AA (es) 1998-07-23
EP1095936A1 (fr) 2001-05-02
WO1997020824A1 (fr) 1997-06-12
NO982590L (no) 1998-08-05
NO982590D0 (no) 1998-06-05
AU725831B2 (en) 2000-10-19
DE69633947D1 (de) 2004-12-30
HUP9902092A3 (en) 2000-12-28
AP9801284A0 (en) 1998-09-30
CN1542002A (zh) 2004-11-03

Similar Documents

Publication Publication Date Title
SK73898A3 (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
US5753653A (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
USH1992H1 (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their pharmaceutical uses
JP5140058B2 (ja) メタロプロテイナーゼ阻害剤
US5985900A (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
JP2002528495A (ja) ニトロソ化およびニトロシル化された非ステロイド抗炎症性化合物、組成物および使用方法
SK286658B6 (sk) Arylpiperazíny, farmaceutický prostriedok, ktorý ich obsahuje, spôsob ich prípravy a ich použitie
JP2000516252A (ja) １，４―複素環式メタロプロテアーゼ阻害剤
BG105788A (bg) Сулфамато хидроксамова киселина като металопротеазен инхибитор
US7132434B2 (en) Metalloproteinase inhibitors
SK12462001A3 (sk) Inhibítory metaloproteáz
US8119673B2 (en) Compounds 148
JP2003505367A (ja) マトリックスメタロプロテイナーゼ阻害剤としての３−アリールスルホニル−２−（置換メチル）プロパン酸誘導体
US6500948B1 (en) Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
EA012266B1 (ru) Сульфониламиноциклические соединения и их применение
EP1660471B1 (fr) Derives d'acide hydroxamique utilises comme inhibiteurs de metalloproteinases
JP2005521641A (ja) 第ｘａ因子阻害剤としての２−（３−スルホニルアミノ−２−オキソピロリジン−１−イル）プロパンアミド
US6344456B1 (en) Piperazinone derivatives and their uses